Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00660543 · ClinicalTrials.gov registry record · NA
MRI Study With Ferumoxytol in Assessing Early Response in Patients With Glioblastoma Multiforme Receiving Temozolomide and Radiation Therapy
A NA study, sponsored by OHSU Knight Cancer Institute.
- Completed
- Registry status
- NA
- Development phase
- 14
- Enrollment target
NCT00660543: Completed NA study, sponsored by OHSU Knight Cancer Institute.
NCT00660543 is a NA study that has completed, run by OHSU Knight Cancer Institute. The registered enrollment target is 14 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00660543, a NA study, has completed, sponsored by OHSU Knight Cancer Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 14 participants
- Enrollment target
Study Summary
This pilot clinical trial studies how a magnetic resonance imaging (MRI) study with ferumoxytol works as a contrasting agent in assessing early response in patients with glioblastoma multiforme receiving temozolomide and radiation therapy. Ferumoxytol is a very small form of iron particles that are injected into the body and taken up by certain tissues which may make these tissues easier to see during imaging. Diagnostic procedures, such as an MRI study with ferumoxytol, may help measure a patient's response to earlier treatment.
Primary Outcome
Radiographical progression is determined based on RANO criteria.
Interventions
- DRUG Gadolinium
- DRUG Ferumoxytol Non-Stoichiometric Magnetite
- OTHER Dynamic Contrast-Enhanced Magnetic Resonance Imaging
- OTHER Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging
- OTHER Diffusion Weighted Imaging
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2006-12 |
| Est. Completion | 2014-06 |
| Phase | NA |
What the finished NCT00660543 record still lists
NCT00660543 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 5 interventions - of which Gadolinium is the first listed.
NCT00660543 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00660543 about?
NCT00660543 is a clinical study titled "MRI Study With Ferumoxytol in Assessing Early Response in Patients With Glioblastoma Multiforme Receiving Temozolomide and Radiation Therapy". This pilot clinical trial studies how a magnetic resonance imaging (MRI) study with ferumoxytol works as a contrasting agent in assessing early response in patients with glioblastoma multiforme receiving temozolomide and radiation therapy. Ferumoxytol is a very small form of iron particles that are ...
What is the current status of trial NCT00660543?
This trial is currently completed. It is a NA study. The enrollment target is 14 participants. The study started on 2006-12. Estimated completion is 2014-06.
What interventions are being tested in trial NCT00660543?
The interventions under investigation include: Gadolinium (DRUG), Ferumoxytol Non-Stoichiometric Magnetite (DRUG), Dynamic Contrast-Enhanced Magnetic Resonance Imaging (OTHER), Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging (OTHER), Diffusion Weighted Imaging (OTHER).
Who is sponsoring clinical trial NCT00660543?
This trial is sponsored by OHSU Knight Cancer Institute, which has 211 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00660543's enrollment target sits among peer trials
14 1909th of 2000 higher than 90 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia